Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acer Therapeutics Inc.OPXA · Entity 108116 | Director | September 30, 2016 | October 04, 2016 |
| NextCure, Inc.NXTC · Entity 7461 | Director · President & CEO | January 30, 2026 | February 03, 2026 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Director | June 21, 2023 | June 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acer Therapeutics Inc.
Report date September 30, 2016 · Filed October 04, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,884 |
Reported balance
After 2016-09-30 transaction · row 1
1 source rowRow 1 · 2016-09-30 · Grant · Acquired 6,455 · Balance 25,884 |
NextCure, Inc.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2036-01-29 | Direct | 38,190 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 38,190 · Balance 38,190 F1: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
PALVELLA THERAPEUTICS, INC.
Report date June 21, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2033-06-21 | Direct | 40,000 |
Reported balance
After 2023-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-21 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENVEC INC
Report date June 16, 2017 · Filed June 20, 2017
Section 16 reporting ended · disclosed 2017-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-06-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-06-16 · Exercise / conversion · Acquired 2,250 · Balance 2,250 Row 2 · 2017-06-16 · Tax withholding · Disposed 1,189 · Balance 1,061 F1: Withholding of Common Stock to pay exercise price. Row 3 · 2017-06-16 · Disposition to issuer · Disposed 1,061 · Balance 0 F2: 2. The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 315 shares of Intrexon common stock having a market value of $7,188 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration"). F3: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law. F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2017-06-16 | Direct | 0 |
Reported balance
After 2017-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-16 · Exercise / conversion · Disposed 2,250 · Balance 0 F5: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of Common Stock to pay exercise price.
F2: 2. The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 315 shares of Intrexon common stock having a market value of $7,188 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration").
F3: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law.
F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration.
F5: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 16:07 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 38,190 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0000905148-26-000480 · form4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,190 Underlying: Common Stock · 38,190 shares Expires 2036-01-29 F1 · derivative.exercise_date: One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 18:22 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 305,500 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000905148-25-000332 · form4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,500 Underlying: Common Stock · 305,500 shares Expires 2035-01-30 F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2026. The remainder vests in 36 monthly installments beginning on February 28, 2026. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:44 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 244,400 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000905148-24-001054 · form4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,400 Underlying: Common Stock · 244,400 shares Expires 2034-03-28 F1 · derivative.exercise_date: The option vests in full on the one year anniversary of the grant, March 29, 2025. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 16:45 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 305,500 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0000905148-24-000395 · form4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,500 Underlying: Common Stock · 305,500 shares Expires 2034-01-30 F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2025. The remainder vests in 36 monthly installments beginning on February 28, 2025. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 16:45 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001437749-23-018280 · rdgdoc.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 18:01 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 309,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001140361-23-009489 · form4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,000 Underlying: Common Stock · 309,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2024. The remainder vests in 36 monthly installments beginning on March 28, 2024. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 19:02 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001583648-22-000049 · wf-form4_165611174598543.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2023 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 16:18 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 262,400 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0000905148-22-000160 · form4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,400 Underlying: Common Stock · 262,400 shares Expires 2032-01-30 F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2023. The remainder vests in 36 monthly installments beginning on February 28, 2023. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 17:33 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004562 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on the date of the Company's 2022 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 16:48 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001123292-21-000496 · edgar.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: One fourth of the option vests on March 15, 2022. The remainder vests in 36 monthly installments beginning on April 15, 2022. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 16:45 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001562180-20-004691 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on June 23, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:35 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000457 · edgar.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 16:18 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001562180-20-000619 · primarydocument.xml · derivative · entry 2 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F2 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 16:18 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 5,431 | $2.11 Strike: $3.23 | $11,443.12 |
DisclosureSEC source: 0001562180-20-000619 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,431 Underlying: Common Stock · 5,431 shares Expires 2030-01-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $11,445.56 in cash compensation for services as a director and committee member, which compensation is payable to the Reporting Person quarterly in arrears pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 16:38 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Options (right to buy) · Derivative | 5,165 | $2.12 Strike: $3.24 | $10,939.47 |
DisclosureSEC source: 0001562180-19-005263 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,165 Underlying: Common Stock · 5,165 shares Expires 2029-10-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $10,937.50 in cash compensation for services as a director and committee member, which compensation is payable to the Reporting Person quarterly in arrears pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 16:13 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 3,789 | $2.89 Strike: $4.40 | $10,950.21 |
DisclosureSEC source: 0001562180-19-004075 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,789 Underlying: Common Stock · 3,789 shares Expires 2029-07-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $10,937.50 in cash compensation for services as a director and committee member, which compensation is payable to the Reporting Person quarterly in arrears pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| April 25, 2019 Filed Apr 30, 2019 17:36 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 5,640 | $1.94 Strike: $2.94 | $10,941.60 |
DisclosureSEC source: 0001562180-19-002447 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,640 Underlying: Common Stock · 5,640 shares Expires 2029-04-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $10,937.50 in cash compensation for services as a director and committee member, which compensation is payable to the Reporting Person quarterly in arrears, pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:45 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001562180-19-000579 · primarydocument.xml · derivative · entry 2 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-25 F2 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:45 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 6,096 | $1.79 Strike: $2.74 | $10,911.84 |
DisclosureSEC source: 0001562180-19-000579 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,096 Underlying: Common Stock · 6,096 shares Expires 2029-01-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $10,937.50 in cash compensation for services as a director and committee member, which compensation is payable to the Reporting Person quarterly in arrears, pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 17:11 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 3,829 | $2.86 Strike: $4.36 | $10,950.94 |
DisclosureSEC source: 0001562180-18-004310 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,829 Underlying: Common Stock · 3,829 shares Expires 2028-10-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $10,937.50 in cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 17:10 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 2,837 | $3.86 Strike: $5.92 | $10,950.82 |
DisclosureSEC source: 0001562180-18-003419 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,837 Underlying: Common Stock · 2,837 shares Expires 2028-07-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $10,937.50 in cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:14 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 2,665 | $4.10 Strike: $6.43 | $10,926.50 |
DisclosureSEC source: 0001562180-18-002005 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,665 Underlying: Common Stock · 2,665 shares Expires 2028-04-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $10,937.50 in cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 16:39 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001562180-18-000481 · primarydocument.xml · derivative · entry 2 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-25 F2 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30 and December 31, 2018. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 16:39 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 2,243 | $5.09 Strike: $7.72 | $11,416.87 |
DisclosureSEC source: 0001562180-18-000481 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,243 Underlying: Common Stock · 2,243 shares Expires 2028-01-25 F1 · price: The stock option was issued to the Reporting Person, who elected to take stock options in lieu of $11,406.25 in cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation policy. Read SEC document |
| October 25, 2017 Filed Oct 27, 2017 16:26 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (Rights to buy) · Derivative | 4,006 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001562180-17-003340 · primarydocument.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,006 Underlying: Common Stock · 4,006 shares Expires 2027-10-25 Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 20:23 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 3,288 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0000899243-17-019252 · doc4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 Underlying: Common Stock · 3,288 shares Expires 2027-07-25 Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:34 UTC | GENVEC INC GNVC · Entity 175088 | Exercise / conversionStock Options (right to buy) · Derivative | 2,250 | $3.80 Strike: $3.80 | $8,550.00 |
DisclosureSEC source: 0001123292-17-001162 · edgar.xml · derivative · entry 4 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2017-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:34 UTC | GENVEC INC GNVC · Entity 175088 | Disposition to issuerCommon Stock | 1,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-17-001162 · edgar.xml · nonDerivative · entry 3 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: 2. The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 315 shares of Intrexon common stock having a market value of $7,188 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration"). F3 · shares: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law. F4 · price: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:34 UTC | GENVEC INC GNVC · Entity 175088 | Tax withholdingCommon Stock | 1,189 | $7.19 | $8,548.91 |
DisclosureSEC source: 0001123292-17-001162 · edgar.xml · nonDerivative · entry 2 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061 F1 · kind: Withholding of Common Stock to pay exercise price. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:34 UTC | GENVEC INC GNVC · Entity 175088 | Exercise / conversionCommon Stock | 2,250 | $3.80 | $8,550.00 |
DisclosureSEC source: 0001123292-17-001162 · edgar.xml · nonDerivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2017 Filed Apr 27, 2017 18:06 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 7,821 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0000899243-17-011040 · doc4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,821 Underlying: Common Stock · 7,821 shares Expires 2027-04-25 Read SEC document |
| January 25, 2017 Filed Jan 30, 2017 19:02 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0000899243-17-002203 · doc4.xml · derivative · entry 2 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-25 F2 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30, and December 31, 2017. Read SEC document |
| January 25, 2017 Filed Jan 30, 2017 19:02 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 9,687 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0000899243-17-002203 · doc4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,687 Underlying: Common Stock · 9,687 shares Expires 2027-01-25 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 19:27 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 9,656 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0000899243-16-032393 · doc4.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,656 Underlying: Common Stock · 9,656 shares Expires 2026-10-25 Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 16:48 UTC | GENVEC INC GNVC · Entity 175088 | GrantStock Options (right to buy) · Derivative | 22,500 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001140361-16-083405 · doc1.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2026-10-20 Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 08:01 UTC | Acer Therapeutics Inc. OPXA · Entity 108116 | GrantCommon Stock | 6,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001354488-16-008339 · issuerdirect_section16.xml · nonDerivative · entry 1 Richman Michael · CIK 0001366265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,884 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.